Mesoblast Heart Failure Trial Delivers Positive Interim Results
Source: The Life Sciences Report��(5/3/17)
Mesoblast Ltd., an Australia-based regenerative medicine company currently in a Phase 3 clinical trial in chronic heart failure, has received successful interim data, which prompted the Maxim Group to comment favorably on the study's design and progress. More >

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market
Source: The Life Sciences Report��(4/19/17)
The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.
More >

String of Positive Trial Results Boosts RepliCel's Profile
Source: The Life Sciences Report��(4/12/17)
Positive results from RepliCel's Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and for hair loss. More >

RXi Pharmaceuticals Receives Japanese Patent for RNAi Platform
Source: The Life Sciences Report��(4/12/17)
With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform. More >

RepliCel's Phase 1 Trial for Hair Loss Completed Successfully
Source: The Life Sciences Report��(3/16/17)
RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development. More >

Regeneus Hits the Fast Track with Major Japanese Partnership
Source: The Life Sciences Report��(2/8/17)
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. More >

Companies Flocking to Japan for Biotech Deals
Source: Colin Lee Novick for The Life Sciences Report��(2/1/17)
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. More >

2017 Small-Cap Biotech Watchlist: Takeaways for Investors
Source: The Life Sciences Report��(1/18/17)
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. More >

Time to Go Long on BrainStorm Cell Therapeutics?
Source: Jason Napodano CFA of BioNap Inc. for The Life Sciences Report��(1/16/17)
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. More >

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Source: The Life Sciences Report��(1/3/17)
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. More >

VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma
Source: The Life Sciences Report��(12/21/16)
VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco. More >

Stock-Moving Catalysts Anticipated for Regeneus in Q4/16
Source: The Life Sciences Report��(9/28/16)
Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan. More >

Regeneus Secures Government Funding for R&D
Source: The Life Sciences Report��(9/14/16)
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding. More >

Investment in Cell and Gene Therapies Ramps Up
Source: George S. Mack of The Life Sciences Report��(6/8/16)
After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way. More >

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Source: George S. Mack of The Life Sciences Report��(5/11/16)
Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully. More >

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer
Source: George S. Mack of The Life Sciences Report ��(4/20/16)
Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose—a fact that oncologists are just now coming to grips with. In this interview with The Life Sciences Report, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men. More >

Seven Biotech Names on the Upswing: 2016 Small-Cap Biotech Watchlist Update
Source: Tracy Salcedo of The Life Sciences Report��(3/9/16)
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China. The Life Sciences Report's 2016 Small-Cap Biotech Watchlist was not immune to that movement, heading into negative territory almost from the moment the selected companies were introduced. But as the market has shown signs of rebounding, so too has the Watchlist.
More >

Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital
Source: George S. Mack of The Life Sciences Report��(3/2/16)
Eden Rahim of Toronto-based Next Edge Capital has had his share of multibagger and grand-slam successes, and is one of the few mutual fund managers who feels comfortable investing in micro-cap biotech names side-by-side with billion-dollar biotech stocks. In this interview with The Life Sciences Report, Rahim describes a group of micro-, small- and mid-cap biotech names possessing powerful growth drivers that could perform even when the overall market is not so hot. More >

Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma
Source: George S. Mack of The Life Sciences Report��(2/17/16)
Stock analysts fall into a few different categories. There are buyside analysts and sellside analysts, and then there are independent analysts commissioned by companies to highlight underexposed business models and growth prospects. The independent analyst, such as Van Leeuwenhoeck's Marcel Wijma, normally works in the small- and micro-cap stock universe, where the buyside and sellside rarely go. In this interview with The Life Sciences Report, Wijma brings to light five diverse, overlooked small-cap biotech stocks from Canada, Europe and Australia that could bring huge returns to investor portfolios. More >

Healthy Biotech Growth from Four Seedling Stocks: Raghuram Selvaraju of Rodman & Renshaw
Source: George S. Mack of The Life Sciences Report��(2/10/16)
It takes nerves of steel to follow micro-cap stocks and ascribe future valuations in hefty multiples. Raghuram "Ram" Selvaraju of Rodman & Renshaw has made the micro- and small-cap biotech universe his specialty, and his track record is impressive. In this interview with The Life Sciences Report, Selvaraju, a former big pharma researcher, details four growth names that could follow in the hallowed footsteps of previous winners. More >

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics
Source: Peter Byrne of The Life Sciences Report��(2/3/16)
Cynata Therapeutics of Australia has carved a technological niche in the fast-advancing cell therapy market with a platform that renders the production of stem cell-based treatments for cancer and diseases of the immune system easy and affordable, saving lives and money. In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. More >

Look North for Value-Priced Growth in Healthcare: StoneCastle's Bruce Campbell
Source: George S. Mack of The Life Sciences Report��(2/3/16)
Canada is a wellspring for natural resources and the industries built around them. But the country also encompasses healthcare-related businesses that are growing, generating cash flow and flourishing. Bruce Campbell of StoneCastle Investment Management has managed both U.S. and Canadian portfolios, and he knows both spheres. As a hedge fund and mutual fund manager concentrating on Canadian companies, he has made a specialty in acquisitions of cash-generating healthcare companies. In this interview with The Life Sciences Report, Campbell discusses seven small-cap growth names, all of which have reached share-price levels that do not reflect their capacity to grow. Some may offer rare opportunities to buy at risk-mitigated value prices. More >

The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase
Source: Tracy Salcedo of The Life Sciences Report��(1/27/16)
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors. Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal. More >

The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News
Source: George S. Mack of The Life Sciences Report��(1/20/16)
Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates. In some cases he will follow a company's clinical development program and data for years before he pulls the trigger and recommends a name. In this interview with The Life Sciences Report, Leong presents a number of names for investors' consideration. Many won't be mentioned in his usual write-ups: It's an early look at what's on his watch list and in his inbox. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place. More >

Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist
Source: Staff of The Life Sciences Report��(12/15/15)
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year. More >